MedTrace Logo

Safety Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women

NCT01397838 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-07-20

No results posted yet for this study

Summary

Recent studies have shown that inhibition of Aquaporine-9 channels may ameliorate the bone degradation process. Pro-bone is an AQ - 9 channels inhibitor. This study is design to evaluate the safety of Pro-bone.

Conditions

  • Osteopenia

Interventions

DRUG

Pro-Bone

500 mg Capsules of Pro-Bone twice daily

Sponsors & Collaborators

  • OsteoBuild Ltd.

    lead INDUSTRY

Principal Investigators

  • Boris Kaplan, Prof. · Rabin Medical Center

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2011-12-31
Completion
2012-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01397838 on ClinicalTrials.gov